Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Radiopharm Theranostics Limited - Sponsored ADR (RADX : NSDQ)

• Company Description    Radiopharm Theranostic is a clinical-stage biopharmaceutical company focused on developing oncology radiopharmaceuticals for areas of high unmet medical need. Radiopharm Theranostic is based in SYDNEY. Number of Employees: 7

• Price / Volume Information    Yesterday's Closing Price: $4.20 Daily Weekly Monthly 20 Day Moving Average: 17,572 shares Shares Outstanding: 7.88 (millions) Market Capitalization: $33.11 (millions) Beta: 52 Week High: $18.90 52 Week Low: $3.50 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -21.20% -24.15% 12 Week -2.33% -17.84% Year To Date % %

• Address & Contact Information Street Address Phone / Fax Email Address Web URL LEVEL 3 62 LYGON STREET - CARLTON VIC,C3 3053 AUS ph: 61-3-9824-5254 fax: - None http://www.radiopharmtheranostics.com

• General Corporate Information    Officers Riccardo Canevari - Chief Executive Officer Paul Hopper - Executive Chairman Phillip Hains - Chief Financial Officer and Company Secretary Hester Larkin - Director Ian Turner - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 75041J101 SIC: 2834 Fiscal Year Fiscal Year End: June Last Reported Quarter: - Next Expected EPS Date: - Share - Related Items Shares Outstanding: 7.88 Most Recent Split Date: (:1) Beta: Market Capitalization: $33.11 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: -

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - - 12/31/24 - - ROA 06/30/25 - - 03/31/25 - - 12/31/24 - - Current Ratio 06/30/25 - - 03/31/25 - - 12/31/24 - - Quick Ratio 06/30/25 - - 03/31/25 - - 12/31/24 - - Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - - 12/31/24 - - Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Capital 06/30/25 - - 03/31/25 - - 12/31/24 - -

Powered by Zacks Investment Research ©